Drugs Made In America Acquisition (DMAA) Payables (2024 - 2025)

Drugs Made In America Acquisition (DMAA) reported Payables of $222184.0 for Q4 2025, down 69.96% on a YoY basis from $739604.0 in Q4 2024, and up 22118.4% quarter-over-quarter from $1000.0 in Q2 2025.

Drugs Made In America Acquisition (DMAA) Payables (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition has reported Payables for 2 years, with the latest figure at $222184.0 in Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 69.96% year-over-year to $222184.0; the trailing twelve-month figure through Dec 2025 stood at $222184.0 (down 69.96% YoY), and the FY2025 full-year result was $222184.0, down 69.96% from the prior year.
  • Payables for Q4 2025 stood at $222184.0, up from $1000.0 in the prior quarter.
  • The five-year high for Payables was $739604.0 in Q4 2024, with the low at $1000.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Payables (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - -
2 Berto Acquisition 312.46 Mn 312.46 Mn - 240,058.00
3 Centurion Acquisition 311.65 Mn 311.65 Mn - 144,789.00
4 GP-Act III Acquisition 311.36 Mn 311.36 Mn - 400,000.00
5 Churchill Capital Corp IX 310.79 Mn 310.79 Mn - -
6 WEN Acquisition 309.15 Mn 309.15 Mn - 50,877.00
7 Bold Eagle Acquisition 275.54 Mn 275.54 Mn - 39,602.00
8 Soulpower Acquisition 264.91 Mn 264.91 Mn - 1.13 Mn
9 BTC Development 262.16 Mn 262.16 Mn - -
10 Drugs Made In America Acquisition 223.11 Mn 223.11 Mn - 222,184.00

Historic Data

Download Data
DateValue
Dec 31, 2025 222,184.00
Jun 30, 2025 1,000.00
Mar 31, 2025 60,898.00
Dec 31, 2024 739,604.00